stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Net margin
Replimune Group, Inc.'s net margin over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2026 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2026) to 0.00% (fiscal 2026) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2026 | 0.00% | 0.00 |
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | 0.00 |
| Jun 2026 | 0.00% | 0.00 |
| Mar 2026 | 0.00% | 0.00 |
| Dec 2025 | 0.00% | 0.00 |
| 34 more quarters | Free account |
Against its own ten years
Low 0.00%
High 0.00%
Ten-year median
0.00%
Current reading's percentile
100
Net margin against peers
| Company | Net margin |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 97.7% |
| ZYME Zymeworks Inc. compare | 16.3% |
| IMNM Immunome, Inc. compare | 0.00% |
| VERA Vera Therapeutics, Inc. compare | 0.00% |
| REPL Replimune Group, Inc. | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −6.81% |
| VIR Vir Biotechnology, Inc. compare | −61.0% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −697.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.35% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue